Cancer

Title
Treatment for Multiple Myeloma Subjects Previously Untreated
Trial Number
204493071812
Number of Participants
750
Principal Investigator

Kevin Barton

M.D.
Hematology/Oncology
Associate Professor
Eligibility

Signed informed consent; age at least 18 years; life-expectancy greater than three months; newly diagnosed, untreated, symptomatic, documented myeloma; and
who are not candidates for high-dose therapy plus SCT because of age (at least 65 years) or coexisting conditions; and measureable disease: serum IgG, IgA, IgM M-protein = 0.5 g/dL or serum IgD M-protein = 0.05 g/dL or = 200 mg urinary M-protein excretion /24-hour.
Must be using two acceptable methods of contraception to avoid pregnancy throughout the study for a period of at least one month (four weeks) before and women for up to eight weeks, men for up to 90 days after the last dose of investigational product; women must not be breastfeeding; subjects must be willing to refrain from blood donations during study drug therapy and for eight weeks after therapy.

Purpose

To determine if the study drug, elotuzumab, given with lenalidomide and dexamethasone is safe and more effective in killing myeloma cells compared with the standard treatment of lenalidomide and dexamethasone alone.

Enrollment

(708) 327-3228

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.